View in EDS HTML Full Text PDF Full Text

Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.

Saved in:
Bibliographic Details
Title: Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
Authors: Drilon A; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States., Cho BC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea., Camidge DR; Anschutz Medical Campus, University of Colorado, Aurora, CO, United States., Nagasaka M; School of Medicine, University of California, Irvine, Orange, CA, United States., Besse B; Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France., Solomon B; Peter MacCallum Cancer Centre, Melbourne, Australia., Goto K; National Cancer Center Hospital East, Kashiwa, Japan., Wolf J; Centrum für Integrierte Onkologie-Uniklinik Köln, Köln, Germany., Popat S; The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom., Felip E; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Yang N; The Second People's Hospital of Hunan Province, Hunan, China., de Langen AJ; Netherlands Cancer Institute, Amsterdam, The Netherlands., Lu S; Department of Oncology, Shanghai Chest Hospital, Shanghai, China., Velcheti V; Mayo Clinic, Jacksonville, FL,United States., Lin AL; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States., Calvet CY; Bristol Myers Squibb, Princeton, NJ, United States., Li L; Bristol Myers Squibb, Princeton, NJ, United States., Tschaika M; Bristol Myers Squibb, Princeton, NJ, United States., Afsar S; Bristol Myers Squibb, Princeton, NJ, United States., Yang H; Bristol Myers Squibb, Princeton, NJ, United States., Lin JJ; Harvard Medical School, Mass General Brigham Cancer Institute, Boston, MA, United States.
Source: The oncologist [Oncologist] 2026 May 08; Vol. 31 (6).
Publication Type: Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41992489
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Drilon+A%22">Drilon A</searchLink>; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Cho+BC%22">Cho BC</searchLink>; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Camidge+DR%22">Camidge DR</searchLink>; Anschutz Medical Campus, University of Colorado, Aurora, CO, United States.<br /><searchLink fieldCode="AU" term="%22Nagasaka+M%22">Nagasaka M</searchLink>; School of Medicine, University of California, Irvine, Orange, CA, United States.<br /><searchLink fieldCode="AU" term="%22Besse+B%22">Besse B</searchLink>; Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Solomon+B%22">Solomon B</searchLink>; Peter MacCallum Cancer Centre, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Goto+K%22">Goto K</searchLink>; National Cancer Center Hospital East, Kashiwa, Japan.<br /><searchLink fieldCode="AU" term="%22Wolf+J%22">Wolf J</searchLink>; Centrum für Integrierte Onkologie-Uniklinik Köln, Köln, Germany.<br /><searchLink fieldCode="AU" term="%22Popat+S%22">Popat S</searchLink>; The Royal Marsden NHS Foundation Trust & The Institute of Cancer Research, London, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Felip+E%22">Felip E</searchLink>; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Yang+N%22">Yang N</searchLink>; The Second People's Hospital of Hunan Province, Hunan, China.<br /><searchLink fieldCode="AU" term="%22de+Langen+AJ%22">de Langen AJ</searchLink>; Netherlands Cancer Institute, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Lu+S%22">Lu S</searchLink>; Department of Oncology, Shanghai Chest Hospital, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Velcheti+V%22">Velcheti V</searchLink>; Mayo Clinic, Jacksonville, FL,United States.<br /><searchLink fieldCode="AU" term="%22Lin+AL%22">Lin AL</searchLink>; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.<br /><searchLink fieldCode="AU" term="%22Calvet+CY%22">Calvet CY</searchLink>; Bristol Myers Squibb, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Bristol Myers Squibb, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Tschaika+M%22">Tschaika M</searchLink>; Bristol Myers Squibb, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Afsar+S%22">Afsar S</searchLink>; Bristol Myers Squibb, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Yang+H%22">Yang H</searchLink>; Bristol Myers Squibb, Princeton, NJ, United States.<br /><searchLink fieldCode="AU" term="%22Lin+JJ%22">Lin JJ</searchLink>; Harvard Medical School, Mass General Brigham Cancer Institute, Boston, MA, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 May 08; Vol. 31 (6).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Multicenter Study; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41992489
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyag137
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Drilon A
      – PersonEntity:
          Name:
            NameFull: Cho BC
      – PersonEntity:
          Name:
            NameFull: Camidge DR
      – PersonEntity:
          Name:
            NameFull: Nagasaka M
      – PersonEntity:
          Name:
            NameFull: Besse B
      – PersonEntity:
          Name:
            NameFull: Solomon B
      – PersonEntity:
          Name:
            NameFull: Goto K
      – PersonEntity:
          Name:
            NameFull: Wolf J
      – PersonEntity:
          Name:
            NameFull: Popat S
      – PersonEntity:
          Name:
            NameFull: Felip E
      – PersonEntity:
          Name:
            NameFull: Yang N
      – PersonEntity:
          Name:
            NameFull: de Langen AJ
      – PersonEntity:
          Name:
            NameFull: Lu S
      – PersonEntity:
          Name:
            NameFull: Velcheti V
      – PersonEntity:
          Name:
            NameFull: Lin AL
      – PersonEntity:
          Name:
            NameFull: Calvet CY
      – PersonEntity:
          Name:
            NameFull: Li L
      – PersonEntity:
          Name:
            NameFull: Tschaika M
      – PersonEntity:
          Name:
            NameFull: Afsar S
      – PersonEntity:
          Name:
            NameFull: Yang H
      – PersonEntity:
          Name:
            NameFull: Lin JJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 08
              M: 05
              Text: 2026 May 08
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1